{Reference Type}: Journal Article
{Title}: Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients.
{Author}: Kamal ME;Werida RH;Radwan MA;Askar SR;Omran GA;El-Mohamdy MA;Hagag RS;
{Journal}: Inflammopharmacology
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 10
{Factor}: 5.093
{DOI}: 10.1007/s10787-024-01508-w
{Abstract}: <B>BACKGROUND: </B>Inflammatory bowel disease (IBD), consists of two primary types: Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab (IFX) and Adalimumab (ADA) are frequently utilized in the management of moderate to severe cases of IBD.<BR><B>OBJECTIVE: </B>This study aimed to assess the efficacy and safety of IFX and ADA in individuals diagnosed with moderate to severe IBD.<BR><B>METHODS: </B>This study is a prospective open-labeled randomized parallel study that included moderate to severe IBD patients treated with either IFX or ADA. A total of 56 patients participated, with 34 patients received IFX and 22 patients received ADA. Various measures, including Crohn's Disease Activity Index (CDAI), Mayo Score/ Disease Activity Index (DAI), and C-reactive protein (CRP) levels, were taken at baseline and week 14 to assess the efficacy of the treatments. In addition, the levels of drugs and sTREM-1 were measured at 14 weeks. Patient safety was monitored throughout the study period.<BR><B>RESULTS: </B>In the group received IFX, there was a notable decrease in CDAI (P = 0.045), DAI (P = 0.026), and CRP (P = 0.023 for CD, and P = 0.021 for UC) levels. In addition, the group received ADA experienced a significant reduction in CDAI (P = 0.001), DAI (P = 0.032), and CRP (P < 0.018 for CD and P = 0.003 for UC) levels. Responders had higher drug concentrations than non-responders, notably IFX concentration was higher in responders with CD (P = 0.001) and UC (P < 0.001). ADA concentration was higher in UC (P <= 0.001) and all CD patients responded to the treatment. The same trend was observed for sTREM-1 levels in CD and UC patients (P = 0.042, and P = 0.015, respectively) in the IFX group. In UC patients treated with ADA, the level of sTREM-1 was significantly low (P = 0.002).<BR><B>CONCLUSIONS: </B>Both IFX and ADA have a good safety profile and deliver a beneficial clinical and laboratory response in moderate-severe IBD patients.<BR><B>BACKGROUND: </B>This study is registered on ClinicalTrials.gov under the identifier NCT05291039. (You can access the study at https://clinicaltrials.gov/study/NCT05291039 (First Posted: March 22, 2022).